Page 78 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $11.18
52wk Low $1.09 GeoVax Labs, Inc. GOVX $2.45
1900 Lake Park Drive
Smyrna, GA 30080

(USD - in millions) www.geovax.com
Market Cap 22.2
Enterprise 13.7
Basic Shares Out. 8.52 COMPANY OVERVIEW
Float 8.48
Institutional Holdings 4.79% Detailed Analysis:Channelchek.com
Short Interest 0.30
Avg. 90-Day Volume 5.33 GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing vaccines and immunotherapies against infectious diseases
and cancers using novel proprietary platforms. GeoVax’s product
pipeline includes ongoing human clinical trials for a next-generation
EPS Data COVID-19 vaccine and therapy for advanced head and neck cancer.
Additional development programs include preventive vaccines against
2022 2023 2024 Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola
CQ1 (5.10) (2.25) (2.47) Sudan, and Marburg), malaria and Zika virus, as well as therapies for
CQ2 (2.70) (3.30) (1.99) various solid tumors.

CQ3 (2.55) (4.80) (0.91)
CQ4 (3.00) (3.94) (1.16)
CY (12.45) (14.29) (8.12) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.33
ROE (ttm) -276.02
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
S
1900 Lake Pa myrna GA 30080

Key Executives
CEO: Dodd, David
CFO: Reynolds, Mark
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures